1. Home
  2. CELU vs SER Comparison

CELU vs SER Comparison

Compare CELU & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.60

Market Cap

50.7M

Sector

Health Care

ML Signal

HOLD

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

HOLD

Current Price

$3.12

Market Cap

42.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CELU
SER
Founded
2016
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.7M
42.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
CELU
SER
Price
$1.60
$3.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$13.00
AVG Volume (30 Days)
62.5K
15.1K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,578,000.00
$116,000.00
Revenue This Year
N/A
$134.46
Revenue Next Year
$76.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$3.12
52 Week High
$4.35
$7.92

Technical Indicators

Market Signals
Indicator
CELU
SER
Relative Strength Index (RSI) 33.82 29.79
Support Level $1.62 $3.15
Resistance Level $2.01 $4.26
Average True Range (ATR) 0.13 0.25
MACD -0.02 -0.03
Stochastic Oscillator 2.82 0.09

Price Performance

Historical Comparison
CELU
SER

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

Share on Social Networks: